GenSight Biologics Reports Sustained Visual Acuity Gain at 78 Weeks in Its Phase I/II Study with GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON)

by Business Wire • 2016/12/20 • 0 Comments

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris: SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today reported additional promising results after 78 weeks of follow-up in its Phase I/II clinical trial. These results confirm the favorable safety and tolerability profile of GS010, while demonstrating sustai

← Salutaris Medical Devices Receives 510(k) Clearance from U.S. FDA for SMD-Sr90-DA Radionuclide Brachytherapy Source

GenSight Biologics annonce un gain d’acuité visuelle à 78 semaines de suivi dans son étude de phase I/II avec GS010 pour le traitement de la Neuropathie Optique Héréditaire de Leber (NOHL) →

Post navigation